Bioshares Etf Profile

BBC -  USA Etf  

USD 19.81  0.23  1.17%

Market Performance
0 of 100
Odds Of Distress
Over 72
Bioshares Biotech is trading at 19.81 as of the 24th of May 2022, a 1.17 percent up since the beginning of the trading day. The etf's open price was 19.58. Bioshares Biotech has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Bioshares Biotech Clinical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2022 and ending today, the 24th of May 2022. Please note, there could be an existing legal relationship between Bioshares Biotech (BBC) and BODISEN BIOTECH INC (BBCZ). Click here to learn more.
Under normal market conditions, the fund will invest not less than 80 percent of its assets in component securities of the index. Bioshares Biotech is traded on NYSEArca Exchange in the United States. More on Bioshares Biotech Clinical

Bioshares Biotech Etf Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Bioshares Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bioshares Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Bioshares Biotech generated a negative expected return over the last 90 days
Bioshares Biotech has high historical volatility and very poor performance
Bioshares Biotech has high likelihood to experience some financial distress in the next 2 years
Bioshares Biotech generated five year return of -3.0%
This fund holds 97.68% of its assets under management (AUM) in equities
Related EntityBBCZ (BODISEN BIOTECH INC)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bioshares Biotech's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
IssuerVirtus
DescriptionVirtus LifeSci Biotech Clinical Trials ETF
Inception Date2014-12-16
BenchmarkLifeSci Biotechnology Clinical Trials Index
Entity TypeRegulated Investment Company
Asset Under Management14.89 Million
Average Trading Valume5,231.5
Asset TypeEquity
CategorySector
FocusHealth Care
Market ConcentrationDeveloped Markets
RegionNorth America
AdministratorVirtus ETF Solutions, LLC
AdvisorVirtus ETF Advisers LLC
CustodianThe Bank of New York Mellon Corporation
DistributorETF Distributors LLC
Portfolio ManagerMatthew B. Brown, Seth Kadushin
Transfer AgentThe Bank of New York Mellon Corporation
Fiscal Year End31-Oct
ExchangeNYSE Arca, Inc.
Number of Constituents181
Market MakerVirtu Financial
Total Expense0.79
Management Fee0.79
Nav Price19.59
Two Hundred Day Average36.03
Ytd-53.70%
Average Daily Volume In Three Month4.17k
Fifty Two Week Low17.8
As Of Date11th of May 2022
Average Daily Volume Last 10 Day7.17k
Fifty Two Week High52.18
One Month-32.34%
Fifty Day Average24.76
Three Month-39.25%
Bioshares Biotech Clinical [BBC] is traded in USA and was established 2014-12-16. The fund is classified under Health category within Virtus family. Bioshares Biotech currently have 16.57 M in assets under management (AUM). , while the total return for the last 3 years was -14.13%.
Check Bioshares Biotech Probability Of Bankruptcy

Geographic Allocation (%)

Sector Allocation (%)

Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Bioshares Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Bioshares Biotech , and the less return is expected.

Top Bioshares Biotech Clinical Constituents

Bioshares Biotech Target Price Odds Analysis

What are Bioshares Biotech's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Bioshares Biotech jumping above the current price in 90 days from now is under 95%. The Bioshares Biotech Clinical probability density function shows the probability of Bioshares Biotech etf to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the etf has a beta coefficient of 1.6156 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bioshares Biotech will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Bioshares Biotech is significantly underperforming DOW.
  Odds Below 19.81HorizonTargetOdds Above 19.81
5.37%90 days
 19.81 
94.60%
Based on a normal probability distribution, the odds of Bioshares Biotech to move above the current price in 90 days from now is under 95 (This Bioshares Biotech Clinical probability density function shows the probability of Bioshares Etf to fall within a particular range of prices over 90 days) .

Bioshares Biotech Major Institutional Holders

Institutional Holdings refers to the ownership stake in Bioshares Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bioshares Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bioshares Biotech's value.
InstituionSecurity TypeTotal SharesValue
Goldman Sachs Group IncFund Units100 K2.8 M
Concourse Financial Group Securities IncPut Options0.00.0
Concourse Financial Group Securities IncCall Options0.00.0
View Bioshares Biotech Diagnostics

Bioshares Biotech Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bioshares Biotech market risk premium is the additional return an investor will receive from holding Bioshares Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bioshares Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Bioshares Biotech's alpha and beta are two of the key measurements used to evaluate Bioshares Biotech's performance over the market, the standard measures of volatility play an important role as well.

Bioshares Biotech Technical Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. Bioshares Biotech Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Bioshares Biotech price patterns.
.

Bioshares Biotech Against Markets

Picking the right benchmark for Bioshares Biotech etf is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bioshares Biotech etf price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bioshares Biotech is critical whether you are bullish or bearish towards Bioshares Biotech Clinical at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bioshares Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Investing Bioshares Biotech Clinical

You need to understand the risk of investing before taking a position in Bioshares Biotech. The danger of trading Bioshares Biotech Clinical is mainly related to its market volatility and ETF specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bioshares Biotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bioshares Biotech. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bioshares Biotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Bioshares Biotech information on this page should be used as a complementary analysis to other Bioshares Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Bioshares Etf analysis

When running Bioshares Biotech price analysis, check to measure Bioshares Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioshares Biotech is operating at the current time. Most of Bioshares Biotech's value examination focuses on studying past and present price action to predict the probability of Bioshares Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bioshares Biotech's price. Additionally, you may evaluate how the addition of Bioshares Biotech to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
The market value of Bioshares Biotech is measured differently than its book value, which is the value of Bioshares that is recorded on the company's balance sheet. Investors also form their own opinion of Bioshares Biotech's value that differs from its market value or its book value, called intrinsic value, which is Bioshares Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioshares Biotech's market value can be influenced by many factors that don't directly affect Bioshares Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioshares Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Bioshares Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioshares Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.